Neoleukin Therapeutics, Inc. (NLTX)
Neoleukin Therapeutics, Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Seattle, WA, US. The stock last traded at $3.49, up 1.45% on the session, giving a market capitalisation of $8.2M. On trailing twelve-month figures it carries a trailing P/E of -4.42, a net margin of 0.0%. Its beta of 1.10 implies it has historically moved more than the broad market.
Neoleukin Therapeutics, Inc. (NLTX) is a biopharmaceutical enterprise focused on developing immune-based treatments for conditions such as cancer, inflammatory responses, and autoimmune diseases, utilizing its proprietary protein design technology. The company's leading investigational therapy is NL-201, a novel protein meticulously crafted to emulate the therapeutic effects of the IL-2/IL-15 cytokines. This product candidate is intended for the management of various malignancies, including renal cell carcinoma and melanoma. The organization, founded in 2003, was previously known as Aquinox Pharmaceuticals, Inc. before officially changing its name to Neoleukin Therapeutics, Inc. in August 2019. Its operations are based out of Seattle, Washington.
Neoleukin Therapeutics, Inc. is most often compared with the following Healthcare names: